[Phase II study of docetaxel plus epirubicin versus docetaxel plus cisplatin as first-line chemotherapy for advanced breast cancer].

Abstract

OBJECTIVE:

To evaluate the efficacy and safety of combination of docetaxel plus epirubicin (TE) versus docetaxel plus cisplatin (TP) as first-line chemotherapy for locally advanced or metastatic breast cancer.

METHODS:

Eighty-eight patients were randomized into two groups with a ratio of 2:1, either to receive TE or TP regimen. The patients received docetaxel 75 mg/m2 plus epirubicin 60 mg/m2 (TE group) or docetaxel 75 mg/m2 plus cisplatin 75 mg/m2 (TP group) administrated intravenously. Both regimens were once repeated 3 weeks later. The efficacy, time to progression and safety were evaluated at the end of the second cycle.

RESULTS:

Complete response was achieved in 5% of TE group and 3.6% of TP. Overall (complete plus partial) response rates in TE and TP group were 48.3% and 60.7%, respectively (P = 0.2788). Disease control rates (CR + PR + SD) for TE and TP groups were 83.6% and 80%, respectively (P = 0.4899). The median time to progression (TTP) was 10 months for TE versus 8 months for TP groups (P = 0.7119). The major grade III or IV toxicities were neutropenia (66.7% in TE; 53.6% in TP, P = 0.2373); and alopecia (30.0% in TE; 10.7% in TP, P = 0.0508).

CONCLUSION:

Both TE and TP regimens as first-line chemotherapy were similarly effective, safe and tolerable in the treatment for locally advanced or metastatic breast cancer.

• Authors: Ya-Jie Wang, Qing Wu, Feng-Xi Su, Li-Zhong Zhou, Zheng-Bao Ye, Jing-Qiao Yang, Hong Ren, Jin Zhang, Gang Ding, Qiang Fu, Ning Wang
• Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology] (Zhonghua Zhong Liu Za Zhi) Vol. 30 Issue 7 Pg. 541-4 (Jul 2008) ISSN: 0253-3766 [Print] China
• PMID: 19062725 (Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Taxoids
• Docetaxel
• Epirubicin
• Cisplatin

Topics

• Adolescent
• Adult
• Aged
• Alopecia (chemically induced)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Breast Neoplasms (drug therapy, pathology, secondary)
• Cisplatin (administration & dosage, adverse effects)
• Docetaxel
• Epirubicin (administration & dosage, adverse effects)
• Female
• Humans
• Middle Aged
• Neoplasm Staging
• Neutropenia (chemically induced)
• Prospective Studies
• Remission Induction
• Taxoids (administration & dosage, adverse effects)
• Young Adult